I’m limiting my posting because some feel I have
Post# of 154646

That said, I feel compelled to point out that little has changed between when we were at .40 and now at .25
Leronlimab is still incredible.
In fact, we’ve only had good news recently with the old CRC data and the Barcelona poster, and word of the new CRC trial finally getting underway.
However, if one just based their assessment of the drug and the company on the general sentiment on this board, you’d think the data showed LL in a poor light or the company is in trouble.
So what are shareholders currently freaking out about?
Let’s start with the CRC trial using 350mg. That’s only the first 5 patients, just to appease the (slow-to-grasp-the-MOA) FDA and those patients will likely have their dose upped as the trial continues. Don’t worry, that trial is sure to deliver amazing data.
Next, the lawsuit. We’ve seen these before. They are exploited by shorts and are mostly ambulance chasing bunk. Ignore it. Even if the company ends up settling, it’s peanuts.
Now, the only fair criticism I think right now is lack of communication from mgmt and IR ignoring emails. However, I have to assume because we did NOT get the expected Shareholder Letter from Jay which would typically have arrived in June, we are in talks and something good is afoot.
Admittedly, it sucks seeing the sp drop so hard and fast. We all have PTSD from the $10 drop. I believe we’re on the cusp of a partnership announcement. Hopefully sooner than later.
So try (not easy) to ignore the sp fluctuations, add if you’re able/comfortable, and don’t stop believin’…
Okay, back to my own silence.

